Onconetix (BWV) Stock Forecast, Price Target & Predictions
BWV Stock Forecast
Onconetix stock forecast is as follows: an average price target of $4.00 (represents a 2205.48% upside from BWV’s last price of $0.17) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BWV Price Target
The average price target for Onconetix (BWV) is $4.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $4.00 to $4.00. This represents a potential 2205.48% upside from BWV's last price of $0.17.
BWV Analyst Ratings
According to 1 Wall Street analysts, Onconetix's rating consensus is 'Buy'. The analyst rating breakdown for BWV stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Onconetix Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 08, 2022 | - | Maxim Group | $4.00 | $1.20 | 233.33% | 2205.48% |
The latest Onconetix stock forecast, released on Dec 08, 2022 by Maxim Group company, set a price target of $4.00, which represents a 233.33% increase from the stock price at the time of the forecast ($1.20), and a 2205.48% increase from BWV last price ($0.17).
Onconetix Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.17 | $0.17 | $0.17 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Onconetix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Onconetix's last price of $0.17. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 08, 2022 | Maxim Group | - | Buy | Initialise |
Onconetix's last stock rating was published by Maxim Group on Dec 08, 2022. The company Initialise its BWV rating from "null" to "Buy".
Onconetix Financial Forecast
Onconetix Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
Onconetix's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. BWV's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Onconetix EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| EBITDA | - | - | - | - | $-4.49M | $-3.15M |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
undefined analysts predict BWV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Onconetix's previous annual EBITDA (undefined) of $NaN.
Onconetix Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| Net Income | - | - | - | - | $-5.35M | $-6.87M |
| Avg Forecast | $24.45M | $21.29M | $-1.75M | $-1.75M | $-1.43M | $18.97M |
| High Forecast | $19.93M | $17.35M | $-1.43M | $-1.75M | $-1.43M | $15.45M |
| Low Forecast | $28.98M | $25.23M | $-2.07M | $-1.75M | $-1.43M | $22.48M |
| Surprise % | - | - | - | - | 3.73% | -0.36% |
Onconetix's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BWV's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Onconetix SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| SG&A | - | - | - | - | $4.27M | $2.30M |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
Onconetix's average Quarter SG&A projection for Dec 23 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to BWV last annual SG&A of $4.27M (Sep 23).
Onconetix EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| EPS | - | - | - | - | $-0.31 | $-0.43 |
| Avg Forecast | $1.54 | $1.34 | $-0.11 | $-0.11 | $-0.09 | $1.19 |
| High Forecast | $1.25 | $1.09 | $-0.09 | $-0.11 | $-0.09 | $0.97 |
| Low Forecast | $1.82 | $1.59 | $-0.13 | $-0.11 | $-0.09 | $1.41 |
| Surprise % | - | - | - | - | 3.44% | -0.36% |
According to undefined Wall Street analysts, Onconetix's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BWV previous annual EPS of $NaN (undefined).